港股午評:恆指漲1.3%,科技股普漲,藥品股集體強勢,寧德時代首日上市大漲17%
港股三大指數高開高走,截止午盤,恆生指數、國企指數、恆生科技指數均上漲1.3%,市場連跌3日後回升顯著。盤面上,作爲市場風向標的大型科技股全線上漲,其中,小米漲3.6%,京東、美團漲2.6%,百度、網易、美團、騰訊皆上漲;研究稱新冠重症患者或可兩款國產抗病毒藥聯用,藥品股全線走強,尤其是三生製藥大漲超35%領銜,泰格醫藥、翰森製藥、石藥集團、先聲藥業、康芝藥業紛紛上漲;全年經調整EBITA盈利8.09億元同比增長61%,阿里影業大漲17%帶領影視股上漲;水務股、汽車股、機器人概念股、電信股、黃金股、半導體股齊漲,比亞迪股份再創歷史新高。寧德時代首日上市大漲超17%,突破300港元。另一方面,此前連續上漲的軍工股集體走低,內房股、航空股、體育用品股部分表現弱勢,三大航空股齊跌。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.